# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Catalent shares rise after Sarepta Therapeutics' Elevidys expanded approval. Despite uncertainties, Catalent's risk/rew...
Aaron Dunn, a portfolio manager at Morgan Stanley, advised investors to diversify beyond the "Magnificent Seven" tech s...